Taken together, these results provided strong evidence that inhibition of the FXR signaling pathway in the intestine together with activation of the FXR signaling pathway and alternative BA synthetic pathway in the liver could be a viable therapy for treating HFD-induced obesity and hypercholesterolemia. The gene discussed is NR1H4; the disease is obesity due to melanocortin 4 receptor deficiency.